On June 16, Peijia Medical released theannouncement of its audited results for the yearended December 31, 2023 (the “Reporting Period”).The results have been audited in accordance withInternational Standards on Auditing issued by theInternational Auditing and Assurance StandardsBoard. The Company’s auditor,PricewaterhouseCoopers, expressed an unqualifiedopinion in the independent auditor’s report.The 2023 Annual Results remain the same as thosedisclosed on March 28, 2024, in the 2023 UnauditedAnnual Results. The audited results of the Companyfor the Reporting Period are summarized below:

• The Group’s revenue increased by 75.9% yoy toRMB 440 million;• The Group’s gross profit increased by 84.7% yoy toRMB 330 million, with the gross profit marginimproving by 3.5 ppts to 73.8%;

• The Group’s expense ratios improved significantly:selling, administrative and R&D expense ratiosdecreased by 22.7, 17.1 and 82.2 ppts yoy,respectively;

•The segment loss of the TVT Business narrowed by13.5% yoy, and the segment loss of NI Businesswas RMB 744,000.Trading in the shares of Peijia Medical (stock code:09996.HK) resumed at 9:00 a.m. on June 17,2024.